Inhibikase Therapeutics, Inc. — Form 10-Q Summary
Reporting period: Three and six months ended June 30, 2022; filed August 12, 2022. The company is a clinical-stage pharmaceutical developer focused primarily on Parkinson’s disease and related disorders, including Multiple Systems Atrophy, and is also developing IkT-001Pro for stable-phase chronic myelogenous leukemia.
Business Context and Development Programs
- Lead candidate IkT-148009 is an oral Abelson tyrosine kinase inhibitor being developed as a potential disease-modifying treatment for Parkinson’s disease and gastrointestinal manifestations.
- The Phase 1b Parkinson’s study closed in June 2022 after two dosing cohorts. The Phase 2a “201 study” began May 23, 2022, with 11 of 40 planned sites open as of August 12, 2022. The study plans to enroll 120 treatment-naive patients and evaluate three doses or placebo over three months; clinical readouts are expected in the second half of 2023.
- The company is conducting animal studies for Multiple Systems Atrophy and is preparing potential U.S. and EU regulatory filings. A proposed Phase 2a MSA study would require additional working capital.
- On June 29, 2022, the company filed an IND for IkT-001Pro, a prodrug of imatinib mesylate for stable-phase CML. Subject to FDA authorization, a bioequivalence study in up to 62 healthy volunteers was expected to begin in the third or fourth quarter of 2022.
Financial Position and Key Metrics
| Metric | Three Months Ended June 30 | Six Months Ended June 30 |
|---|---|---|
| Grant revenue | $6,552 vs. $1.36 million in 2021 | $52,583 vs. $2.77 million in 2021 |
| Research and development expense | $2.98 million vs. $2.38 million | $6.00 million vs. $4.81 million |
| Selling, general and administrative expense | $1.66 million vs. $1.61 million | $3.33 million vs. $3.21 million |
| Net loss | $4.64 million vs. $2.64 million | $9.28 million vs. $5.27 million |
| Basic and diluted loss per share | $0.18 loss vs. $0.22 loss | $0.37 loss vs. $0.47 loss |
| Operating cash flow | Not separately presented for the quarter | $8.29 million used vs. $8.18 million used |
- Cash was $32.21 million at June 30, 2022, down from $40.75 million at December 31, 2021.
- Working capital was $29.46 million; accumulated deficit was $39.10 million.
- Total liabilities were $4.49 million, including $860,444 of accounts payable and $3.63 million of accrued expenses and other current liabilities.
- Notes payable were eliminated; the CEO note was settled in full on January 3, 2022.
- Total stockholders’ equity was $29.50 million at June 30, 2022, compared with $38.42 million at December 31, 2021.
- The company had no commercial product revenue and continues to report recurring losses.
Material Changes Versus the Prior Comparable Period
- Grant revenue declined 99.5% in the second quarter and 98.1% year to date, primarily because company resources shifted toward Parkinson’s clinical development rather than grant-funded activities.
- Research and development expense increased 25.2% in the quarter and 24.6% year to date, driven mainly by higher non-grant-related costs associated with the Parkinson’s clinical trial.
- Net loss increased 76.0% for the quarter and 76.0% year to date, reflecting sharply lower grant revenue and increased research and development spending.
- Operating cash use increased modestly year to date, while 2021 financing cash flow benefited from approximately $41.1 million of proceeds from the June 2021 public offering. No securities were sold under the company’s ATM program during the first six months of 2022.
- The company entered into a May 2022 ATM agreement permitting sales of up to $9.8 million of common stock, subject to market conditions and applicable offering limitations.
Liquidity, Outlook, Risks, and Unusual Items
- Management estimated that available working capital was sufficient to fund normal operations through December 31, 2023, but stated that substantial additional funding will be required for continued development programs, including the proposed MSA study and additional IkT-148009 studies.
- Potential funding sources include public or private equity, debt, grants, licenses, and collaborations. Additional financing may be unavailable or may dilute existing stockholders or impose restrictive obligations.
- The company expects research and development expenses and losses to increase as clinical programs advance. The filing does not provide product-sales guidance or a forecast for achieving profitability.
- Key development risks include clinical-trial enrollment and execution, regulatory approval, safety and efficacy outcomes, manufacturing and supply-chain constraints, intellectual-property protection, competition, and the absence of commercial revenue.
- COVID-19, inflation, supply-chain disruption, and the Russia-Ukraine conflict may delay trials, increase costs, impair capital-market access, or disrupt suppliers and clinical operations.
- The company entered into a Lexington, Massachusetts office lease with expected minimum payments totaling $447,090 through 2025. The lease accounting commencement date had not occurred as of June 30, 2022; a right-of-use asset and lease liability were expected to be recorded in the third quarter of 2022.
- As of July 22, 2022, the common stock had traded below Nasdaq’s $1.00 minimum bid price for 30 consecutive trading days. The company received a compliance period ending January 23, 2023 to regain compliance, creating a potential delisting risk.
- There were no reported legal proceedings, defaults, or off-balance-sheet arrangements. Management concluded that disclosure controls and procedures were effective as of June 30, 2022.
Investor Verification Checklist
- Verify progress, enrollment, timing, and data quality for the Phase 2a Parkinson’s “201 study,” including the expected second-half-2023 readout.
- Confirm FDA status and timing for the IkT-001Pro IND and whether the planned bioequivalence study began.
- Assess the pace of cash burn relative to the $32.21 million cash balance and the company’s stated December 31, 2023 funding horizon.
- Monitor use of the $9.8 million ATM facility, potential equity dilution, and any additional financing required for the MSA and Parkinson’s programs.
- Track Nasdaq minimum-bid-price compliance and any subsequent listing extension, reverse split, or delisting action.
- Evaluate whether clinical results support the company’s disease-modifying claims, which remain unproven in humans as of the filing.